Generic Injectable Sales Set to Grow Three-fold Between 2019 and 2029, Finds Fact.MR

Continued supply-demand imbalance in the drug sector is alarming, and pushing key manufacturers to emphasize expansion of manufacturing and distribution capabilities.
Spread the Word
Listed Under



Dublin 2 - Dublin - Ireland


DUBLIN 2, Ireland - May 29, 2020 - PRLog -- Currently at a nascent stage, the global generic injectable market is projected to witness exponential growth in sales at around 12% CAGR during 2020– 2025. Over the course of forecast period, generic injectable sales will experience 3X growth, as indicated by a new Fact.MR study. Increasing patient preference for self-administration of drugs is primarily developing a fertile ground for the generic injectable market, says the report.

"The generic pharmaceuticals sector is gaining a boost from frequent FDA approvals. Launch of low-cost injectables through investments in consolidations and mergers has been a major highlight," states the Fact.MR report.

Key Takeaways: Generic Injectable Market

·        Demand for monoclonal antibodies (mAbs) would remain significant; vaccines are gaining traction.

·        Generic injectable market continues to see emergence of high-value opportunities in North America and Europe.

·        Asian markets would capture investors' attention, owing to solid growth in pharma production capacities and technology penetration.

·        High preference for small molecule drugs will prevail

·        Generic injectables continue to witness significant adoption in pain management.

·        Large molecule injectables are set to outperform their small counterparts by 2022.

Key Market Growth Drivers

·        Expansion of orphan drug and parenteral products spaces remains a strong factor driving generic injectable sales.

·        Increasing preference for cost-efficient biologics such as mAbs and vaccines over drugs is in favor of market growth.

·        Reduced development time and increasing manufacturers' investments in consolidation are bolstering demand for generic injectables.

Key Restraints

·        Hefty operational costs will remain the key constraint facing generic injectable manufacturers.

·        Tightening competition from low-cost manufacturers continues to challenge large-scale players in generic injectable market.

Read Report-

Competition Analysis: Generic Injectable Market

This Fact.MR study has covered some of the most prominent companies active in the generic injectable market, which include, but are not limited to, Pfizer Inc., Hospira Inc., Hikma, and Mylan. Key market players continue to maintain their strategic focus on expansion of business through mergers.

Development of new development pipelines and extension of product portfolios continue to be the key strategies of players that look forward to unlock opportunities in the US generic injectable market. Increasing competition to penetrate developed regional markets is attracting investments towards introduction of patented complex biologics. Association with CMOs and CDMOs will be a profitable developmental strategy in terms of productivity and operational costs, says the report.

Request Sample Report-

Email:*** Email Verified
Location:Dublin 2 - Dublin - Ireland
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fact.MR PRs
Trending News
Most Viewed
Top Daily News

Like PRLog?
Click to Share